Prostate Cancer

Charles J. Ryan, MD, will soon be joining the University of Minnesota Medical School as director of the Hematology, Oncology, and Transplantation Division in the Department of Medicine, effective April 2018.

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in patients with localized prostate cancer.<br /> &#8203;

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of&nbsp;medicine and&nbsp;urology, Mount Sinai School of Medicine, discusses the use of abiraterone and docetaxel in patients with&nbsp;metastatic castration-resistant prostate cancer.&nbsp;

Prachi Mishra, PhD, was awarded the first &ldquo;Colonel (Ret.) David G. McLeod Prostate Cancer Translational Research Fellowship&rdquo; at the Uniformed Services University of Health Sciences on December 7. She was presented this award in front of Department of Defense leadership, industry leaders, cancer scientists, military healthcare providers, and other colleagues.

With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.

Determining the sequence of therapies has yet to be wholly standardized for treating castration-resistant prostate cancer (CRPC), particularly in the case of abiraterone (Zytiga) and enzalutamide (Xtandi).

Therapeutic Management of Nonmetastatic Prostate Cancer

Therapeutic Approach for Nonmetastatic Prostate Cancer

Based on data from the phase III SPARTAN trial, apalutamide has been granted a priority review by the FDA for the&nbsp;treatment of patients with nonmetastatic castration-resistant prostate cancer, according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.

According to results of a phase I/II study, men with metastatic castration-resistant prostate cancer who received a second course of radium-223&nbsp;(Xofigo) experienced minimal hematologic toxicity and low radiographic bone progression rates.

Janssen Biotech has submitted a new drug application to the FDA for&nbsp;apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer, the manufacturer of the next-generation oral androgen receptor inhibitor announced today.

A look back at all the FDA news that occurred in the month of September.